Investor Presentaiton
·
Key Highlights of Q3FY22 and 9MFY22
•
Revenue from Operations grew by 13.0% YoY during the quarter, with EBITDA margin at 19.0% and Net Profit growth of 16.6% YoY
India Business: Company's secondary sales in Q3FY22 registered growth of 16.0% YoY compared to IPM growth of 10.4% YoY
(Source: IQVIA data)
Strong volume led growth in the acute therapies partially helped by COVID-19
•
Faster than market growth in chronic therapies during 9MFY22
•
Trade Generic business continues to deliver robust growth despite the high base of last year
•
Recently launched Pulmocare division (in respiratory segment) saw encouraging response with higher than market growth rate
US Business - Continue to face pricing pressure on the base business, partially being mitigated by new product launches
R&D expenses in the quarter was 1.4 billion at 5.5% of revenue from operations
The Company filed 1 ANDAs with the US FDA and received 6 approvals (including 1 tentative approvals) in Q3FY22
Healthy Balance Sheet with net cash of 14.9 billion as on December 31, 2021
O
e
ALKEMView entire presentation